Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06974305 · ClinicalTrials.gov registry record
PET/MRI/EEG Imaging Study in Epilepsy
A clinical trial of Epilepsy, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT06974305: Recruiting study of Epilepsy, sponsored by Massachusetts General Hospital.
NCT06974305 is a study of Epilepsy that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06974305, a study of Epilepsy, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to better understand how epilepsy alters brain function through neuroimaging of healthy people and people with epilepsy. The study investigates how changes in brain metabolism (sugar consumption, measured by positron emission tomography \[FDG-PET\], and blood flow, measured by functional magnetic resonance imaging \[fMRI\]) relate to abnormal interictal electrical activity associated with epilepsy (measured by electroencephalography \[EEG\]). The study will also compare how the three imaging modalities localize regions of abnormal function in the brain.
Primary Outcome
There are no interventions in this study and thus no outcome measures. Primary goal of the study will be achieved with image analysis on the PET/MRI/EEG data.
Conditions Studied
Interventions
- RADIATION FDG-PET/fMRI/EEG imaging
Study Locations (1)
Massachusetts
- Athinoula A. Martinos Center - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2025-11-30 |
What NCT06974305 shows while recruiting
NCT06974305 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which FDG-PET/fMRI/EEG imaging is the first listed.
NCT06974305 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06974305 about?
NCT06974305 is a clinical study titled "PET/MRI/EEG Imaging Study in Epilepsy". This study aims to better understand how epilepsy alters brain function through neuroimaging of healthy people and people with epilepsy. The study investigates how changes in brain metabolism (sugar consumption, measured by positron emission tomography \[FDG-PET\], and blood flow, measured by functi...
What is the current status of trial NCT06974305?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2023-09-21. Estimated completion is 2025-11-30.
What conditions does trial NCT06974305 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT06974305?
The interventions under investigation include: FDG-PET/fMRI/EEG imaging (RADIATION).
Who is sponsoring clinical trial NCT06974305?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06974305 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06974305's enrollment target sits among peer trials
30 109th of 160 higher than 41 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
RECRUITING
-
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
RECRUITING
-
SeizEAR Safety Study
RECRUITING · NA
-
Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
RECRUITING
-
Tumor Related Epilepsy
RECRUITING
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI